For years, scientists have known that allergies involve a chain reaction in the body where immune cells sound the alarm and trigger symptoms like sneezing, wheezing, and itchy eyes. But a team at Karolinska Institutet in Sweden has now uncovered something new about a overlooked player in that chain — and it involves a chemical you might recognize from antidepressant ads.

The researchers found that a type of immune cell called Tc2 cells, which contribute to allergic inflammation, depends heavily on how the body processes fats and a brain chemical called serotonin to stay active. Serotonin is best known for its role in mood, but the study shows it also helps fuel these allergy-driving cells.

"Our study shows that Tc2 cells depend on lipid metabolism as well as the breakdown of serotonin to function," said Chris Tibbitt, a researcher at Karolinska Institutet's Department of Medicine in Huddinge. "These new findings highlight that Tc2 cells have distinct biological requirements that may influence how allergic inflammation develops and persists."

The study, published in the journal Allergy, examined how these cells draw energy to sustain inflammation over time. Unlike better-known immune cells that have received heavy research attention, Tc2 cells have stayed largely in the shadows — even as evidence grows that they play a key role in conditions like asthma.

"Tc2 cells remain far less studied than other allergy-associated immune cells, despite growing evidence of their role in diseases like asthma," Tibbitt said.

One interesting side finding: When the researchers looked at data from a group called the BAMSE cohort, they noticed that people who had been prescribed SSRIs — a common type of antidepressant that affects serotonin — showed altered Tc2 responses and lower rates of allergic sensitization. The team is quick to note this is a preliminary observation that needs more research, so it's not a reason to change how doctors prescribe.

The findings are still early and won't lead to new treatments right away. But by learning more about what makes Tc2 cells tick, scientists hope to eventually develop better ways to identify or even target harmful inflammation in allergic disease. In a world where hundreds of millions of people live with allergies, even small steps toward understanding can open doors down the road.

The study was co-authored by Sabrina de Souza Ferreira and colleagues, with funding support noted in the original publication.